These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 18479257)

  • 21. miR-301a promotes intestinal mucosal inflammation through induction of IL-17A and TNF-α in IBD.
    He C; Shi Y; Wu R; Sun M; Fang L; Wu W; Liu C; Tang M; Li Z; Wang P; Cong Y; Liu Z
    Gut; 2016 Dec; 65(12):1938-1950. PubMed ID: 26338824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases.
    Sarra M; Monteleone I; Stolfi C; Fantini MC; Sileri P; Sica G; Tersigni R; Macdonald TT; Pallone F; Monteleone G
    Inflamm Bowel Dis; 2010 Aug; 16(8):1332-9. PubMed ID: 20186935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Progress on relationship between IL-23/IL-17 axis and inflammatory bowel disease].
    Wang N; Zhang W; Chen Y; Cao Y; Hu Z; Jiang F
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2021 Mar; 37(3):271-277. PubMed ID: 33766235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulation of gut inflammation and th17 cell response by interleukin-21.
    Fina D; Sarra M; Fantini MC; Rizzo A; Caruso R; Caprioli F; Stolfi C; Cardolini I; Dottori M; Boirivant M; Pallone F; Macdonald TT; Monteleone G
    Gastroenterology; 2008 Apr; 134(4):1038-48. PubMed ID: 18395085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation.
    Kikly K; Liu L; Na S; Sedgwick JD
    Curr Opin Immunol; 2006 Dec; 18(6):670-5. PubMed ID: 17010592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin-23 and Th17 cells in the control of gut inflammation.
    Monteleone I; Pallone F; Monteleone G
    Mediators Inflamm; 2009; 2009():297645. PubMed ID: 19503799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential role of NK cells in the pathogenesis of inflammatory bowel disease.
    Yadav PK; Chen C; Liu Z
    J Biomed Biotechnol; 2011; 2011():348530. PubMed ID: 21687547
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunopathogenesis of inflammatory bowel disease.
    Shih DQ; Targan SR
    World J Gastroenterol; 2008 Jan; 14(3):390-400. PubMed ID: 18200661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cells of the innate and adaptive immunity and their interactions in inflammatory bowel disease.
    Kmieć Z; Cyman M; Ślebioda TJ
    Adv Med Sci; 2017 Mar; 62(1):1-16. PubMed ID: 28126697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TL1A (TNFSF15) and DR3 (TNFRSF25): A Co-stimulatory System of Cytokines With Diverse Functions in Gut Mucosal Immunity.
    Valatas V; Kolios G; Bamias G
    Front Immunol; 2019; 10():583. PubMed ID: 30972074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Understanding the IL-23-IL-17 immune pathway.
    McKenzie BS; Kastelein RA; Cua DJ
    Trends Immunol; 2006 Jan; 27(1):17-23. PubMed ID: 16290228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The link between IL-23 and Th17 cell-mediated immune pathologies.
    McGeachy MJ; Cua DJ
    Semin Immunol; 2007 Dec; 19(6):372-6. PubMed ID: 18319054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Involvement of the IL-23/IL-17 axis and the Th17/Treg balance in the pathogenesis and control of autoimmune arthritis.
    Astry B; Venkatesha SH; Moudgil KD
    Cytokine; 2015 Jul; 74(1):54-61. PubMed ID: 25595306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23-->IL-17 axis.
    Sheibanie AF; Yen JH; Khayrullina T; Emig F; Zhang M; Tuma R; Ganea D
    J Immunol; 2007 Jun; 178(12):8138-47. PubMed ID: 17548652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Delivery of IL-12p40 ameliorates DSS-induced colitis by suppressing IL-17A expression and inflammation in the intestinal mucosa.
    Kim DJ; Kim KS; Song MY; Seo SH; Kim SJ; Yang BG; Jang MH; Sung YC
    Clin Immunol; 2012 Sep; 144(3):190-9. PubMed ID: 22836084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Innate lymphocytes induce inflammatory bowel disease.
    Diefenbach A; Vonarbourg C
    Immunol Cell Biol; 2010 Oct; 88(7):694-6. PubMed ID: 20585336
    [No Abstract]   [Full Text] [Related]  

  • 37. Targeting the development and effector functions of TH17 cells.
    Ghilardi N; Ouyang W
    Semin Immunol; 2007 Dec; 19(6):383-93. PubMed ID: 18083530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biologic therapy for inflammatory bowel disease.
    Ardizzone S; Bianchi Porro G
    Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional relevance of T helper 17 (Th17) cells and the IL-17 cytokine family in inflammatory bowel disease.
    Hundorfean G; Neurath MF; Mudter J
    Inflamm Bowel Dis; 2012 Jan; 18(1):180-6. PubMed ID: 21381156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. miR-10a inhibits dendritic cell activation and Th1/Th17 cell immune responses in IBD.
    Wu W; He C; Liu C; Cao AT; Xue X; Evans-Marin HL; Sun M; Fang L; Yao S; Pinchuk IV; Powell DW; Liu Z; Cong Y
    Gut; 2015 Nov; 64(11):1755-64. PubMed ID: 25281418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.